Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Deep Genomics will use the money to advance drug candidates created through its AI drug development model, based on research by Toronto faculty.

Lilly Asia Ventures took part in a series B-plus round that marks the first for biopharmaceutical company Transcenta Holding, formed through the merger of two of the corporate's portfolio companies.

The avatar software provider has ramped up its series B round to $40m, adding Salesforce Ventures to a consortium that already included Daimler.

Bloomberg Beta-backed Deep Genomics will use the series B funding to advance drug candidates created through its artificial intelligence drug development model.

University of Auckland Inventors Fund has contributed to a $40m series B round for AI-based avatar developer Soul Machines, with the investment led by Temasek.

The colectomy-focused robotic surgical device developer has now assembled $51.7m having spun out from University of Nebraska Medical Center in 2006.

The colectomy-focused surgical device developer, which counts SinoPharm as an earlier investor, has secured series B-plus funding, in a round led by Bluestem Capital.

Novo Seeds returned for a series B round that will support the progress of NorthSea Therapeutics' lead liver disease candidate through clinical trials.

The eye disease drug developer has closed a round led by existing backer Boehringer Ingelheim Venture Fund to take its total funding above $42m.